FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis

FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis

Abstract Background Acute pancreatitis (AP) presents a significant clinical challenge with limited therapeutic options. The complex etiology and pathophysiology of AP emphasize the need for innovative treatments. This study explores mRNA-based therapies delivering fibroblast growth factor 21 (FGF21)...

Full description

Saved in:
Bibliographic Details
Main Authors: Amaya Lopez-Pascual, Eva Santamaria, Nuria Ardaiz, Iker Uriarte, Tiffany Palmer, Anne-Renee Graham, Celia Gomar, Roberto C. Barbero, M. Ujue Latasa, Maria Arechederra, Jesus M. Urman, Carmen Berasain, Antonio Fontanellas, Carlos L. del Rio, Maite G. Fernandez-Barrena, Paolo G.V. Martini, Joshua R. Schultz, Pedro Berraondo, Matias A. Avila
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Translational Medicine
Subjects:
Acute pancreatitis
mRNA therapy
FGF21
APOA1
Cytoprotection
Pancreatic injury
Online Access:https://doi.org/10.1186/s12967-025-06129-7
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items